Circulating microRNAs as potential new biomarkers for prostate cancer

127Citations
Citations of this article
169Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Since they were first described in the 1990s, circulating microRNAs (miRNAs) have provided an active and rapidly evolving area of current research that has the potential to transform cancer diagnostics and therapeutics. In particular, miRNAs could provide potential new biomarkers for prostate cancer, the most common cause of cancer in UK men. Current diagnostic tests for prostate cancer have low specificity and poor sensitivity. Further, although many prostate cancers are so slow growing as not to pose a major risk to health, there is currently no test to distinguish between these and cancers that will become aggressive and life threatening. Circulating miRNAs are highly stable and are both detectable and quantifiable in a range of accessible bio fluids, thus have the potential to be useful diagnostic, prognostic and predictive biomarkers. This review aims to summarise the current understanding of circulating miRNAs in prostate cancer patients and their potential role as biomarkers. © 2013 Cancer Research UK. All rights reserved.

Cite

CITATION STYLE

APA

Sita-Lumsden, A., Dart, D. A., Waxman, J., & Bevan, C. L. (2013, May). Circulating microRNAs as potential new biomarkers for prostate cancer. British Journal of Cancer. https://doi.org/10.1038/bjc.2013.192

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free